世界のムコ多糖症治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Mucopolysaccharidosis Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5870 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、ムコ多糖症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（静脈注射、脳室内（ICV））、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・ムコ多糖症治療薬の市場動向 ・企業の競争状況、市場シェア ・ムコ多糖症治療薬の種類別市場規模と予測2016-2027（静脈注射、脳室内（ICV）） ・ムコ多糖症治療薬の用途別市場規模と予測2016-2027（病院、クリニック、その他） ・ムコ多糖症治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・ムコ多糖症治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・ムコ多糖症治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・ムコ多糖症治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・ムコ多糖症治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Shire (Takeda Pharmaceutical Company Limited)、Denali Therapeutics、ArmaGen、REGENXBIO Inc.、Sangamo Therapeutics、BioMarin、Lysogene、Abeona Therapeutics Inc.、Ultragenyx Pharmaceutical、Genzyme Corporation） ・結論

MPS, also known as mucopolysaccharidosis, refers to a group of key rare metabolic disorders which is caused by the absence, deficiency or malfunctioning of lysosomal enzymes called glycosaminoglycan (GAGs).

Market Analysis and Insights: Global Mucopolysaccharidosis Therapeutics Market
The global Mucopolysaccharidosis Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Mucopolysaccharidosis Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Mucopolysaccharidosis Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Mucopolysaccharidosis Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Mucopolysaccharidosis Therapeutics market.

Global Mucopolysaccharidosis Therapeutics Scope and Market Size
Mucopolysaccharidosis Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Mucopolysaccharidosis Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Intravenous
Intracerebroventricular (ICV)

Segment by Application
Hospital
Clinic
Other

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Shire (Takeda Pharmaceutical Company Limited)
Denali Therapeutics
ArmaGen
REGENXBIO Inc.
Sangamo Therapeutics
BioMarin
Lysogene
Abeona Therapeutics Inc.
Ultragenyx Pharmaceutical
Genzyme Corporation

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Intravenous
1.2.3 Intracerebroventricular (ICV)
1.3 Market by Application
1.3.1 Global Mucopolysaccharidosis Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Mucopolysaccharidosis Therapeutics Market Perspective (2016-2027)
2.2 Mucopolysaccharidosis Therapeutics Growth Trends by Regions
2.2.1 Mucopolysaccharidosis Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Mucopolysaccharidosis Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Mucopolysaccharidosis Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Mucopolysaccharidosis Therapeutics Industry Dynamic
2.3.1 Mucopolysaccharidosis Therapeutics Market Trends
2.3.2 Mucopolysaccharidosis Therapeutics Market Drivers
2.3.3 Mucopolysaccharidosis Therapeutics Market Challenges
2.3.4 Mucopolysaccharidosis Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Mucopolysaccharidosis Therapeutics Players by Revenue
3.1.1 Global Top Mucopolysaccharidosis Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Mucopolysaccharidosis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Mucopolysaccharidosis Therapeutics Revenue
3.4 Global Mucopolysaccharidosis Therapeutics Market Concentration Ratio
3.4.1 Global Mucopolysaccharidosis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mucopolysaccharidosis Therapeutics Revenue in 2020
3.5 Mucopolysaccharidosis Therapeutics Key Players Head office and Area Served
3.6 Key Players Mucopolysaccharidosis Therapeutics Product Solution and Service
3.7 Date of Enter into Mucopolysaccharidosis Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Mucopolysaccharidosis Therapeutics Breakdown Data by Type
4.1 Global Mucopolysaccharidosis Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Type (2022-2027)

5 Mucopolysaccharidosis Therapeutics Breakdown Data by Application
5.1 Global Mucopolysaccharidosis Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Mucopolysaccharidosis Therapeutics Market Size (2016-2027)
6.2 North America Mucopolysaccharidosis Therapeutics Market Size by Type
6.2.1 North America Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Mucopolysaccharidosis Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2027)
6.3 North America Mucopolysaccharidosis Therapeutics Market Size by Application
6.3.1 North America Mucopolysaccharidosis Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Mucopolysaccharidosis Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Mucopolysaccharidosis Therapeutics Market Size by Application (2016-2027)
6.4 North America Mucopolysaccharidosis Therapeutics Market Size by Country
6.4.1 North America Mucopolysaccharidosis Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Mucopolysaccharidosis Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Mucopolysaccharidosis Therapeutics Market Size (2016-2027)
7.2 Europe Mucopolysaccharidosis Therapeutics Market Size by Type
7.2.1 Europe Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Mucopolysaccharidosis Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2027)
7.3 Europe Mucopolysaccharidosis Therapeutics Market Size by Application
7.3.1 Europe Mucopolysaccharidosis Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Mucopolysaccharidosis Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Mucopolysaccharidosis Therapeutics Market Size by Application (2016-2027)
7.4 Europe Mucopolysaccharidosis Therapeutics Market Size by Country
7.4.1 Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Type
8.2.1 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Application
8.3.1 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region
8.4.1 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Mucopolysaccharidosis Therapeutics Market Size (2016-2027)
9.2 Latin America Mucopolysaccharidosis Therapeutics Market Size by Type
9.2.1 Latin America Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Mucopolysaccharidosis Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Mucopolysaccharidosis Therapeutics Market Size by Application
9.3.1 Latin America Mucopolysaccharidosis Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Mucopolysaccharidosis Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Mucopolysaccharidosis Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Mucopolysaccharidosis Therapeutics Market Size by Country
9.4.1 Latin America Mucopolysaccharidosis Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Mucopolysaccharidosis Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Type
10.2.1 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Application
10.3.1 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country
10.4.1 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Shire (Takeda Pharmaceutical Company Limited)
11.1.1 Shire (Takeda Pharmaceutical Company Limited) Company Details
11.1.2 Shire (Takeda Pharmaceutical Company Limited) Business Overview
11.1.3 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Introduction
11.1.4 Shire (Takeda Pharmaceutical Company Limited) Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021)
11.1.5 Shire (Takeda Pharmaceutical Company Limited) Recent Development
11.2 Denali Therapeutics
11.2.1 Denali Therapeutics Company Details
11.2.2 Denali Therapeutics Business Overview
11.2.3 Denali Therapeutics Mucopolysaccharidosis Therapeutics Introduction
11.2.4 Denali Therapeutics Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021)
11.2.5 Denali Therapeutics Recent Development
11.3 ArmaGen
11.3.1 ArmaGen Company Details
11.3.2 ArmaGen Business Overview
11.3.3 ArmaGen Mucopolysaccharidosis Therapeutics Introduction
11.3.4 ArmaGen Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021)
11.3.5 ArmaGen Recent Development
11.4 REGENXBIO Inc.
11.4.1 REGENXBIO Inc. Company Details
11.4.2 REGENXBIO Inc. Business Overview
11.4.3 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Introduction
11.4.4 REGENXBIO Inc. Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021)
11.4.5 REGENXBIO Inc. Recent Development
11.5 Sangamo Therapeutics
11.5.1 Sangamo Therapeutics Company Details
11.5.2 Sangamo Therapeutics Business Overview
11.5.3 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Introduction
11.5.4 Sangamo Therapeutics Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021)
11.5.5 Sangamo Therapeutics Recent Development
11.6 BioMarin
11.6.1 BioMarin Company Details
11.6.2 BioMarin Business Overview
11.6.3 BioMarin Mucopolysaccharidosis Therapeutics Introduction
11.6.4 BioMarin Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021)
11.6.5 BioMarin Recent Development
11.7 Lysogene
11.7.1 Lysogene Company Details
11.7.2 Lysogene Business Overview
11.7.3 Lysogene Mucopolysaccharidosis Therapeutics Introduction
11.7.4 Lysogene Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021)
11.7.5 Lysogene Recent Development
11.8 Abeona Therapeutics Inc.
11.8.1 Abeona Therapeutics Inc. Company Details
11.8.2 Abeona Therapeutics Inc. Business Overview
11.8.3 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Introduction
11.8.4 Abeona Therapeutics Inc. Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021)
11.8.5 Abeona Therapeutics Inc. Recent Development
11.9 Ultragenyx Pharmaceutical
11.9.1 Ultragenyx Pharmaceutical Company Details
11.9.2 Ultragenyx Pharmaceutical Business Overview
11.9.3 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Introduction
11.9.4 Ultragenyx Pharmaceutical Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021)
11.9.5 Ultragenyx Pharmaceutical Recent Development
11.10 Genzyme Corporation
11.10.1 Genzyme Corporation Company Details
11.10.2 Genzyme Corporation Business Overview
11.10.3 Genzyme Corporation Mucopolysaccharidosis Therapeutics Introduction
11.10.4 Genzyme Corporation Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021)
11.10.5 Genzyme Corporation Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Intravenous
Table 3. Key Players of Intracerebroventricular (ICV)
Table 4. Global Mucopolysaccharidosis Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Mucopolysaccharidosis Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Mucopolysaccharidosis Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Mucopolysaccharidosis Therapeutics Market Share by Regions (2016-2021)
Table 8. Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Mucopolysaccharidosis Therapeutics Market Share by Regions (2022-2027)
Table 10. Mucopolysaccharidosis Therapeutics Market Trends
Table 11. Mucopolysaccharidosis Therapeutics Market Drivers
Table 12. Mucopolysaccharidosis Therapeutics Market Challenges
Table 13. Mucopolysaccharidosis Therapeutics Market Restraints
Table 14. Global Mucopolysaccharidosis Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Mucopolysaccharidosis Therapeutics Market Share by Players (2016-2021)
Table 16. Global Top Mucopolysaccharidosis Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Mucopolysaccharidosis Therapeutics as of 2020)
Table 17. Ranking of Global Top Mucopolysaccharidosis Therapeutics Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Mucopolysaccharidosis Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Mucopolysaccharidosis Therapeutics Product Solution and Service
Table 21. Date of Enter into Mucopolysaccharidosis Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2016-2021)
Table 25. Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Mucopolysaccharidosis Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2016-2021)
Table 29. Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Mucopolysaccharidosis Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Mucopolysaccharidosis Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Mucopolysaccharidosis Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Mucopolysaccharidosis Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Mucopolysaccharidosis Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Mucopolysaccharidosis Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Mucopolysaccharidosis Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Mucopolysaccharidosis Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Mucopolysaccharidosis Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Mucopolysaccharidosis Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Mucopolysaccharidosis Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Mucopolysaccharidosis Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Mucopolysaccharidosis Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 61. Shire (Takeda Pharmaceutical Company Limited) Company Details
Table 62. Shire (Takeda Pharmaceutical Company Limited) Business Overview
Table 63. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product
Table 64. Shire (Takeda Pharmaceutical Company Limited) Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021) & (US$ Million)
Table 65. Shire (Takeda Pharmaceutical Company Limited) Recent Development
Table 66. Denali Therapeutics Company Details
Table 67. Denali Therapeutics Business Overview
Table 68. Denali Therapeutics Mucopolysaccharidosis Therapeutics Product
Table 69. Denali Therapeutics Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021) & (US$ Million)
Table 70. Denali Therapeutics Recent Development
Table 71. ArmaGen Company Details
Table 72. ArmaGen Business Overview
Table 73. ArmaGen Mucopolysaccharidosis Therapeutics Product
Table 74. ArmaGen Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021) & (US$ Million)
Table 75. ArmaGen Recent Development
Table 76. REGENXBIO Inc. Company Details
Table 77. REGENXBIO Inc. Business Overview
Table 78. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product
Table 79. REGENXBIO Inc. Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021) & (US$ Million)
Table 80. REGENXBIO Inc. Recent Development
Table 81. Sangamo Therapeutics Company Details
Table 82. Sangamo Therapeutics Business Overview
Table 83. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product
Table 84. Sangamo Therapeutics Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021) & (US$ Million)
Table 85. Sangamo Therapeutics Recent Development
Table 86. BioMarin Company Details
Table 87. BioMarin Business Overview
Table 88. BioMarin Mucopolysaccharidosis Therapeutics Product
Table 89. BioMarin Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021) & (US$ Million)
Table 90. BioMarin Recent Development
Table 91. Lysogene Company Details
Table 92. Lysogene Business Overview
Table 93. Lysogene Mucopolysaccharidosis Therapeutics Product
Table 94. Lysogene Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021) & (US$ Million)
Table 95. Lysogene Recent Development
Table 96. Abeona Therapeutics Inc. Company Details
Table 97. Abeona Therapeutics Inc. Business Overview
Table 98. Abeona Therapeutics Inc. Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021) & (US$ Million)
Table 99. Abeona Therapeutics Inc. Recent Development
Table 100. Ultragenyx Pharmaceutical Company Details
Table 101. Ultragenyx Pharmaceutical Business Overview
Table 102. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product
Table 103. Ultragenyx Pharmaceutical Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021) & (US$ Million)
Table 104. Ultragenyx Pharmaceutical Recent Development
Table 105. Genzyme Corporation Company Details
Table 106. Genzyme Corporation Business Overview
Table 107. Genzyme Corporation Mucopolysaccharidosis Therapeutics Product
Table 108. Genzyme Corporation Revenue in Mucopolysaccharidosis Therapeutics Business (2016-2021) & (US$ Million)
Table 109. Genzyme Corporation Recent Development
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Mucopolysaccharidosis Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Intravenous Features
Figure 3. Intracerebroventricular (ICV) Features
Figure 4. Global Mucopolysaccharidosis Therapeutics Market Share by Application: 2020 VS 2027
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Other Case Studies
Figure 8. Mucopolysaccharidosis Therapeutics Report Years Considered
Figure 9. Global Mucopolysaccharidosis Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Mucopolysaccharidosis Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Mucopolysaccharidosis Therapeutics Market Share by Regions: 2020 VS 2027
Figure 12. Global Mucopolysaccharidosis Therapeutics Market Share by Regions (2022-2027)
Figure 13. Global Mucopolysaccharidosis Therapeutics Market Share by Players in 2020
Figure 14. Global Top Mucopolysaccharidosis Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Mucopolysaccharidosis Therapeutics as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Mucopolysaccharidosis Therapeutics Revenue in 2020
Figure 16. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2016-2021)
Figure 17. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2022-2027)
Figure 18. North America Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Mucopolysaccharidosis Therapeutics Market Share by Type (2016-2027)
Figure 20. North America Mucopolysaccharidosis Therapeutics Market Share by Application (2016-2027)
Figure 21. North America Mucopolysaccharidosis Therapeutics Market Share by Country (2016-2027)
Figure 22. United States Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Mucopolysaccharidosis Therapeutics Market Share by Type (2016-2027)
Figure 26. Europe Mucopolysaccharidosis Therapeutics Market Share by Application (2016-2027)
Figure 27. Europe Mucopolysaccharidosis Therapeutics Market Share by Country (2016-2027)
Figure 28. Germany Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Share by Region (2016-2027)
Figure 38. China Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Mucopolysaccharidosis Therapeutics Market Share by Type (2016-2027)
Figure 46. Latin America Mucopolysaccharidosis Therapeutics Market Share by Application (2016-2027)
Figure 47. Latin America Mucopolysaccharidosis Therapeutics Market Share by Country (2016-2027)
Figure 48. Mexico Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Share by Country (2016-2027)
Figure 54. Turkey Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Mucopolysaccharidosis Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Shire (Takeda Pharmaceutical Company Limited) Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2016-2021)
Figure 58. Denali Therapeutics Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2016-2021)
Figure 59. ArmaGen Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2016-2021)
Figure 60. REGENXBIO Inc. Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2016-2021)
Figure 61. Sangamo Therapeutics Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2016-2021)
Figure 62. BioMarin Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2016-2021)
Figure 63. Lysogene Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2016-2021)
Figure 64. Abeona Therapeutics Inc. Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2016-2021)
Figure 65. Ultragenyx Pharmaceutical Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2016-2021)
Figure 66. Genzyme Corporation Revenue Growth Rate in Mucopolysaccharidosis Therapeutics Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

---